TScan Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Cancer
Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas
Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support...
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim...
Spexis announces positive renal impairment clinical trial results with balixafortide
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support...
eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference
- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022...
BC Cancer Foundation Launches Historic $500 Million Fundraising Campaign to Take Cancer Research and Care Beyond Belief
Launching the most ambitious and comprehensive health campaign in British Columbia’s historyOne in two British Columbians will face cancer in...
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles...
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both...
AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering...
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post...
Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022
MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapyTrial will be conducted...
PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a...
Advanced Dermatology and Cosmetic Surgery Provides Breast Cancer Patients and Survivors with Free Skin Cancer Screenings for Breast Cancer Awareness Month
Physician-led network offering complimentary skin cancer screenings across its network of clinics throughout OctoberMAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE)...
Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration
HAYWARD, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company committed to advancing precision medicine...
DynamiCure Announces Appointment of Industry Veteran Peter Lasky as its First Chief People Officer
Appointment strengthens senior leadership team as company advances its first candidate into the clinic and prepares to expand its pipeline...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
Reimbursement granted with no restrictions to the labelATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”),...
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
Funds will advance research into ELI-007 as a mutant BRAF-peptide vaccine and ELI-008 as a p53 hotspot mutation-peptide vaccine, with...
Humacyte Expands Board of Directors and Leadership Team with New Appointments
Lt. General Bruce Green, M.D., USAF-ret. Joins Board of Directors Cindy Cao, Ph.D. Appointed as Chief Regulatory Officer DURHAM, N.C.,...
Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes
Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in...